Plus Therapeutics Q3 net loss $0.04/shr; cash $16.6M; CNSide commercial launch advances

PLUS THERAPEUTICS, INC.

2025-Q3 EPS reported -$0.29 revenue$3,846,000

Net loss of $4.4M ($0.04/shr) vs $2.9M ($0.37/shr) in Q3 2024; operating loss $4.5M.
Cash and investments $16.6M (up from $6.9M on June 30, 2025 and $3.6M at Dec 31, 2024).
First national coverage agreement with UnitedHealthcare for CNSide diagnostics, covering 51M+ lives.
Houston lab received CLIA certification, enabling Medicare/Medicaid access and commercial payor coverage.
Positive ReSPECT-LM Phase 1 results for REYOBIQ presented at SNO/ASCO; advance payment of $1.9M from CPRIT.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-258568
form_type: 8-K
ticker: PSTV
cik: 0001095981
company_name: PLUS THERAPEUTICS, INC.
filed_at: 2025-10-30T23:59:59+00:00
discovered_at: 2026-05-14T18:02:38.782811+00:00
generated_at: 2026-05-17T01:13:57.032284+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-258568
json_url: https://secwatch.observer/filing/0001193125-25-258568.json
markdown_url: https://secwatch.observer/filing/0001193125-25-258568.md
text_url: https://secwatch.observer/filing/0001193125-25-258568.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312525258568/0001193125-25-258568-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312525258568/pstv-20251030.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-258568

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.